The search strategy used a combination of following keywords: “Randomized Controlled Trials”, “RCT”, “Type 2 Diabetes Mellitus”, “T2DM”, “sodium-glucose cotransporter-2 inhibitors”, “SGLT-2i”, “Canagliflozin”, “Dapagliflozin”, “Empagliflozin”, AND “major adverse cardiovascular events”, “mace”, “cardiovascular disease”, “coronary artery disease”, “coronary heart disease”, “myocardial infarction”, “cerebrovascular disease”, “mortality”, and “safety”. The keywords were checked for controlled vocabulary under Medical Subject Headings (MeSH) of PubMed. Here, SLC5A2 is linked to type 2 diabetes mellitus.